1 | 2 | 3 | 4 | 5 | 6 |
| General clinical studies |
3.1.6. | Determination of osmotic resistance of red blood cells by the photometric method | Study | 24.31 | 1.37 | 25.68 |
| Research |
| Hemostasiogram (paragraphs 1.2. + 1.4.1. + 1.5. + 6.40.1. + 6.40.2. + 6.40.3. + 6.6.4.)* | Study | 22.20 | 30.99 | 53.19 |
| Coprogram (paragraphs 1.2. + 2.8.1. + 2.8.2. + 2.8.3.) | Study | 27.63 | 7.95 | 35.58 |
| General blood test with platelets (paragraphs 1.2.+ 1.4.+ 3.7.+ 3.9.1.+ 3.26.3.+ 3.6.1.)* | Study | 50.07 | 6.64 | 56.71 |
| General blood test (paragraphs 1.2.+ 1.4 ..+ 3.7.+ 3.9.1.+ 3.26.3.) | Study | 31.98 | 6.10 | 38.08 |
| General urine analysis (paragraphs 1. 2. +2. 1. 9. +2. 1. 4. 1. +2. 1.10. 1.)* | Study | 18.07 | 2.71 | 20.78 |
| Determination of blood groups according to the system A on Cross-Cross, determination of the Rh factor (Clause 1.2.+P..1.4.2.+C.1.5.+Clause 7.2.)* | Study | 25.79 | 9.61 | 35.40 |
| Rebraga test (paragraphs 1.2. + 1.4. + 1.5. + (5.13.3.1.3.) X2) | Study | 15.73 | 3.93 | 19.66 |
| Screening test for determining syphilis (RPR-Carbon) (Clause 1.2.+ Clause 1.4.3.+ Clause 1.5.+ Clause 8.17.9.1.11) | Study | 34.02 | 7.22 | 41.24 |
1. | Separate operations |
1.1.2. | Pipeting semi -automatic dispensers | pipetting | 0.22 | 0.07 | 0.29 |
1.1.3. | Pipeting by automatic dispensers | pipetting | 0.09 | 0.07 | 0.16 |
1.2.* | Registration (preliminary and final) of the material, patient’s passport data and research results in journals and banks or PCs* | Registration | 4.52 | 0.53 | 5.05 |
1.2.1. | Registration (provision of results by e -mail)* | Study | 4.52 | 0 | 4.52 |
1.3. | Blood from a finger |
1.3.2. | Taking blood from a finger for the entire spectrum of hematological studies in the concept of "general blood test", including a leukocyte formula | Study | 4.01 | 3.03 | 7.04 |
*1.3.1. | Taking blood from a finger (antibodies) | Study | 1.92 | 1.08 | 3.00 |
1.4. | Vienna |
| Registration + processing of venous blood to obtain plasma or serum * | Study | 7.51 | 0.55 | 8.06 |
1.4.* | Blood sampling from a vein (biochemical blood test, UAC)* | Study | 4.35 | 1.32 | 5.67 |
1.4.* | Blood sampling from a vein (biochemical blood test, UAC) ** | Study | 4.35 | 1.32 | 5.67 |
1.4.* | Blood fence from vein (biochemical blood test, UAC) *** | Study | 4.35 | 1.32 | 5.67 |
1.4.* | Blood fence from vein (biochemical blood test, UAC) **** | Study | 4.35 | 1.32 | 5.67 |
1.4.1. | Blood sampling from a vein (hemostasiogram, many and other separate indicators of a swelling system) | Study | 4.35 | 1.24 | 5.59 |
1.4.2. | Blood fence from vein (blood type, Rh factor, antibodies) | Study | 4.35 | 1.44 | 5.79 |
1.4.3. | Blood sampling from Vienna (immunochemistry, hormones, oncarkers, if (chlamydia, APS, autoimmune tests))* | Study | 4.35 | 1.24 | 5.59 |
1.4.3. | Blood sampling from Vienna (immunochemistry, hormones, oncarkers, if (chlamydia, APS, autoimmune tests)) ** | Study | 4.35 | 1.24 | 5.59 |
1.4.4. | Blood fence from vein (glycated hemoglobin, cardiodrica)) | Study | 4.35 | 1.24 | 5.59 |
1.5. | Celent blood processing to obtain plasma or serum* | Study | 2.99 | 0.02 | 3.01 |
2.1. | Urine research |
2.1.2. | Glucose detection with expess test in the urine | Study | 2.50 | 1.00 | 3.50 |
2.1.3.1. | Detection of protein with an expess test in the urine | Study | 2.50 | 1.00 | 3.50 |
2.1.4.1. | Determination of protein with sulfacylic acid in the urine* | Study | 6.53 | 0.42 | 6.95 |
2.1.6. | Detection of ketone bodies with an express test in the urine | Study | 2.50 | 1.00 | 3.50 |
2.1.7. | Detection of bilirubin with an express test in the urine | Study | 2.50 | 1.00 | 3.50 |
2.1.8. | Detection of urobilin bodies with an express test in the urine | Study | 2.50 | 1.00 | 3.50 |
2.1.9. | The study of the complex of parameters of general urine analysis by means of semi -automatic analyzers based on dry chemistry methods | Study | 2.99 | 1.21 | 4.20 |
2.1.10.1. | Microscopic examination of sediment in the urine normally | Study | 4.01 | 0.55 | 4.56 |
2.1.11. | Calculation of the number of uniform elements by Nechiporenko (urine analysis by Nechiporenko) | Study | 14.59 | 0.39 | 14.98 |
2.1.12. | Determining the concentration ability of the kidneys by Zimnitsky | Study | 10.06 | 0.03 | 10.09 |
2.10. | Detection of Trichomonas and Gonococci in the drugs of the separated genital organs painted with methylene blue according to gram |
2.10.1. | Detection of Trichomonas, gonococci in the drugs of the separated genitourinary organs painted with methylene blue (gynecol. Mais on the flora of 1 hearth)) | Study | 17.37 | 0.24 | 17.61 |
2.10.2. | Detection of Trichomonas, Gonococci in the drugs of the separated genitourinary organs painted according to gram (gynecols. Mais on the flora of 1 hearth) | Study | 22.70 | 0.93 | 23.63 |
2.2. | Study of spinal fluid |
2.2.1. | Determination of color, transparency, relative density, fibrous film in the cerebrospinal fluid | Study | 2.99 | 0.01 | 3.00 |
2.2.2. | Detection of protein by reaction of Pandy in the cerebrospinal fluid | Study | 2.50 | 0.03 | 2.53 |
2.2.3.1. | Determination of protein with sulfacylic acid in cerebrospinal fluid | Study | 6.04 | 0.10 | 6.14 |
2.2.4. | Determination of the number of cellular elements (cytosis) and their differentiated calculation in the native drug in the cerebrospinal fluid | Study | 19.36 | 0.65 | 01.20 |
2.2.5. | Microscopic examination in a painted drug in cerebrospinal fluid | Study | 15.20 | 1.09 | 16.29 |
2.3. | Research of exudates and transfer |
2.3.1. | Determination of the number, character, color, transparency, relative density of exudants and Tansesuds | Study | 2.02 | 0.33 | 2.35 |
2.3.2. | The detection of protein by reaction of the rivals of exudants and Tansesuds | Study | 4.01 | 0.56 | 4.57 |
2.3.3. | Microscopic study | Study | 31.16 | 2.04 | 33.20 |
2.4. | Sputum research |
2.4.1. | Determination of the number, character, color, consistency, smell in sputum | Study | 2.02 | 0.88 | 2.90 |
2.4.2.1. | Microscopic examination of sputum in a native drug | Study | 8.55 | 1.18 | 9.73 |
2.4.2.2. | Microscopic examination in sputum in a painted drug | Study | 10.06 | 0.58 | 10.64 |
2.4.3.2. | Microscopy on acid-resistant microbacteria in the drugs painted according to cylies-nilsen. | Study | 22.15 | 1.28 | 23.43 |
2.7. | The study of synovial fluid |
2.7.1. | Determination of physicochemical properties in synovial fluid | Study | 4.01 | 1.90 | 5.91 |
2.7.2. | Microscopic examination with the calculation of the number of uniforms (cytosis) in the native drug in the synovial fluid | Study | 15.57 | 0.34 | 15.91 |
2.7.3. | Microscopic examination in a painted drug in synovial fluid | Study | 12.07 | 0.91 | 12.98 |
2.8. | Study of feces |
2.8.1. | Determination of color, consistency, smell, impurities, mucus, pH in feces | Study | 2.02 | 0.10 | 2.12 |
2.8.2. | Detection of blood in the feces (AT to NB Human) | Study | 2.99 | 4.06 | 7.05 |
2.8.2.1. | Bleeding test in feces (Lactoferin, Transferin, Calpropoxin) | Study | 2.99 | 48.06 | 51.05 |
2.8.3. | Microscopic examination of feces (in 3 drugs) | Study | 18.11 | 3.28 | 21.39 |
2.8.4.1. | Detection of protozoa in feces (cryptosporidia) | Study | 8.06 | 9.11 | 17.17 |
2.8.4.2. | Detection of protozoa in feces (lamblia) | Study | 8.06 | 6.52 | 14.58 |
2.8.5. | Helminthic detection by the CATO method (1 drug) in feces | Study | 11.05 | 0.36 | 11.41 |
2.9. | Study of feces for enterobiosis |
2.9.1. | Study of scraping for enterobiosis (in 3 drugs) | Study | 11.05 | 1.11 | 12.16 |
3. | Hematological studies |
3.4. | Counting reticulocytes in the blood* | Study | 14.04 | 2.21 | 16.25 |
3.5. | Calculation of red blood cells with basophilic grain in the blood | Study | 16.10 | 0.56 | 16.66 |
3.6.1. | Counting blood platelets in painted strokes by phonio | Study | 18.11 | 0.56 | 18.67 |
3.7. | Determining the rate of erythrocyte in the blood (ESR) | Study | 2.02 | 1.91 | 3.93 |
3.9.1. | Calculation of a leukocyte formula with a description of the morphology of blood cells for non -hemological diseases | Study | 7.04 | 0.56 | 7.60 |
3.13. | Calculation of LE cells by Novoselova | Study | 63.27 | 2.45 | 65.72 |
3.14.1. | Blood examination for malaria parasites with the preparation of a thick drop | Study | 25.30 | 1.53 | 26.83 |
3.14.2. | Blood examination for malaria parasites in painted smear | Study | 21.52 | 1.53 | 23.05 |
3.26.3. | Blood test using hematological analyzers of automatic, with differentiation of the leukocyte formula | Study | 14.04 | 1.79 | 15.83 |
5.10.1. | Determination of cardiomarkers by dry chemistry |
5.10.1.2. | Troponin, Mioglobin, MV fraction of creative phosphokinase (quantitative definition of (simultaneous) cardiomarkers, dry chemistry method) | Study | 34.20 | 39.45 | 73.65 |
5.10.2. | Determination of cardiomarkers by the immunochemical method |
5.10.2.1. | Troponin is ultra -sensitive in venous blood (determination of cardiomarkers by the immunochemical method) | Study | 34.17 | 13.63 | 47.80 |
5.10.2.2. | Mioglobin in venous blood (determination of cardiomarkers by the immunochemical method)* | Study | 34.17 | 18.18 | 52.35 |
5.10.2.3. | KFK-MW (concentration by mass) in venous blood (determination of cardiomarkers by the immunochemical method) | Study | 34.17 | 13.21 | 47.38 |
5.10.2.4. | BNP (cerebral sodium peptide) in venous blood (determination of cardiomarkers by the immunochemical method) | Study | 34.17 | 43.61 | 77.78 |
5.10.2.5. | NT-PROBNP (pro-brain sodium-reuretic peptide) in venous blood (determination of cardiomarkers by the immunochemical method)* | Study | 34.17 | 35.90 | 70.07 |
5.11.2. | Determination of carcomorkers (oncomarkers) by immuno -function analysis, automated calculation |
5.11.2.1. | Alfa-phytoprotein (AFP) (determination of carcomorkers (oncomarkers) by immuno-function analysis, automated calculation)* | Study | 20.11 | 13.05 | 33.16 |
5.11.2.2. | Chancerombreal antigen (KEA) (determination of carcomorkers (oncomarkers) by immuno -functional analysis, automated calculation* | Study | 20.11 | 13.38 | 33.49 |
5.11.2.3. | CA 19-9 (determination of carcomorkers (oncomarkers) by immuno-function analysis, automated calculation)* | Study | 20.11 | 27.11 | 47.22 |
5.11.2.4. | CA - 125 (determination of carcomorkers (oncomarkers) by immuno -function analysis, automated calculation)* | Study | 20.11 | 26.56 | 46.67 |
5.11.2.5. | CA 15-3 (determination of carcomorkers (oncomarkers) by immunoeroferment analysis automated calculation)* | Study | 20.11 | 27.25 | 47.36 |
5.11.2.6. | Prostatic antigen General (PSA) (determination of carcomorkers (oncomarkers) by immuno -functional analysis, automated calculation)* | Study | 20.11 | 14.73 | 34.84 |
5.11.2.7. | Prostatic Antigen Free (St. PCA) (determination of carcomorkers (oncomarkers) by immuno -functional analysis, automated calculation)* | Study | 20.11 | 16.79 | 36.90 |
5.11.2.8. | B-2-microglobulin | Study | 20.11 | 8.38 | 28.49 |
5.11.2.9. | CA 242* | Study | 20.11 | 13.98 | 34.09 |
5.11.2.10. | Cyfra 21-1* | Study | 20.11 | 22.53 | 42.64 |
5.11.2.11. | He-4* | Study | 20.11 | 28.84 | 48.95 |
5.11.2.12. | Determination of calcitonin | Study | 20.11 | 08/15 | 35.19 |
5.13.3.1. | Conducting research using multi -channel biochemical autoanizers with non -dummy registration of research results |
5.13.1.1. | Glycated hemoglobin (HB A1) (determination of the concentration of glycated hemoglobin)* | Study | 1.92 | 7.52 | 9.44 |
5.13.3.1.1 | Total protein (biochemical blood test)* | Study | 1.92 | 0.34 | 2.26 |
5.13.3.1.2. | Albumin (biochemical blood test)* | Study | 1.92 | 0.24 | 2.16 |
5.13.3.1.3. | Creatinine (biochemical blood test)* | Study | 1.92 | 1.03 | 2.95 |
5.13.3.1.4. | Urea (biochemical blood test)* | Study | 1.92 | 0.46 | 2.38 |
5.13.3.1.5. | Uric acid (biochemical blood test)* | Study | 1.92 | 0.39 | 2.31 |
5.13.3.1.6. | General cholesterol (biochemical blood test)* | Study | 1.92 | 0.47 | 2.39 |
5.13.3.1.7. | High density cholesterol (HDL) (biochemical blood test)* | Study | 1.92 | 1.39 | 3.31 |
5.13.3.1.8. | LDL cholesterol LDL (LDL) (biochemical blood test)* | Study | 1.92 | 3.80 | 5.72 |
5.13.3.1.9. | Serum glucose (biochemical blood test)* | Study | 1.92 | 0.16 | 2.08 |
5.13.3.1.10. | General bilirubin (biochemical blood test)* | Study | 1.92 | 0.21 | 2.13 |
5.13.3.1.11. | Direct bilirubin (biochemical blood test)* | Study | 1.92 | 0.36 | 2.28 |
5.13.3.1.13. | Calcium (biochemical blood test)* | Study | 1.92 | 0.45 | 2.37 |
5.13.3.1.14 | Potassium (biochemical blood test)* | Study | 1.92 | 0.99 | 2.91 |
5.13.3.1.15 | Sodium (biochemical blood test)* | Study | 1.92 | 0.99 | 2.91 |
5.13.3.1.16 | Chlorides (biochemical blood test)* | Study | 1.92 | 0.99 | 2.91 |
5.13.3.1.17 | Phosphorus inorganic (biochemical blood test)* | Study | 1.92 | 0.20 | 2.12 |
5.13.3.1.18 | Alaninaminotransferase ALT (biochemical blood test)* | Study | 1.92 | 0.31 | 2.23 |
5.13.3.1.19 | AST ASPAPATAMINTRESSFERASE (Biochemical Blood Analysis)* | Study | 1.92 | 0.33 | 2.25 |
5.13.3.1.20 | Alpha-amylase in blood serum (biochemical blood test)* | Study | 1.92 | 0.99 | 2.91 |
5.13.3.1.22 | Pancreatic amylase (biochemical blood test)* | Study | 1.92 | 4.75 | 6.67 |
5.13.3.1.23 | Lipaza* | Study | 1.92 | 1.24 | 3.16 |
5.13.3.1.24 | Alkaline phosphatase (determination of activity) (biochemical blood test)* | Study | 1.92 | 0.40 | 2.32 |
5.13.3.1.25 | Gamma-glutamintranspeptidase GGTP (determination of activity) (biochemical blood test)* | Study | 1.92 | 0.56 | 2.48 |
5.13.3.1.26 | HBDH (determination of activity) (biochemical blood test)* | Study | 1.92 | 1.02 | 2.94 |
5.13.3.1.27 | Lactate dehydrogenase LDH (determination of activity) (biochemical blood test)* | Study | 1.92 | 0.51 | 2.43 |
5.13.3.1.28 | CFC creatine phosphokinase (determination of activity) (biochemical blood test)* | Study | 1.92 | 0.88 | 2.80 |
5.13.3.1.29 | KFK-MV (determination of activity) (biochemical blood test)* | Study | 1.92 | 4.02 | 5.94 |
5.13.3.1.30 | Serum iron in blood serum (level determination) (biochemical blood test)* | Study | 1.92 | 2.31 | 4.23 |
5.13.3.1.31 | Triglycerides (biochemical blood test)* | Study | 1.92 | 0.96 | 2.88 |
5.13.3.1.32 | Ferritin (biochemical blood test)* | Study | 1.92 | 7.42 | 9.34 |
5.13.3.1.33 | Transerrin (biochemical blood test)* | Study | 1.92 | 5.92 | 7.84 |
5.13.3.1.34 | Mioglobin (biochemical blood test)* | Study | 1.92 | 16.61 | 18.53 |
5.13.3.1.35 | Microalbumin in the urine* | Study | 1.92 | 4.44 | 6.36 |
5.13.3.1.36 | Magnesium (biochemical blood test)* | Study | 1.92 | 0.66 | 2.58 |
5.13.3.1.37 | Apoprotein A1 (biochemical blood test)* | Study | 1.92 | 6.49 | 8.41 |
5.13.3.1.38 | Apoprotein B (biochemical blood test)* | Study | 1.92 | 6.05 | 7.97 |
5.13.3.1.41 | Copper (biochemical blood test)* | Study | 1.92 | 3.57 | 5.49 |
5.13.3.1.42 | Alpha - 1 - antitripsin (biochemical blood test) | Study | 1.92 | 14.46 | 16.38 |
5.13.3.1.43 | Cerulloplasmin (biochemical blood test)* | Study | 1.92 | 7.37 | 9.29 |
5.13.3.1.44. | Glucose (glucosotolerant test - GTT) 2 -multiple | Study | 1.92 | 8.87 | 10.79 |
5.13.3.1.46 | Fructosamine | Study | 1.92 | 4.90 | 6.82 |
5.13.3.1.47 | Tsistatin C* | Study | 1.92 | 9.94 | 11.86 |
5.13.3.1.50 | General iron -binding capacity (OHSSS, UIBC)* | Study | 1.92 | 6.77 | 8.69 |
5.2. | Biochemical studies using photoelectrocolorimeters and single -channel biochemical automatic filmmers |
5.2.7. | Determination of glucose in solid blood express method | Study | 7.46 | 2.19 | 9.65 |
5.6. | Biochemical studies The determination of indicators of the acid-base state of the blood through automatic analyzers |
5.6. | Determination of indicators of the acid-base state (COST) | Study | 6.99 | 30.87 | 37.86 |
5.6.1. | Determination of indicators of the acid-base state of the blood through automatic analyzers (KSHS) | Study | 6.99 | 30.91 | 37.90 |
5.9.1. | Determination of hormones by immuno -function analysis with automated calculation |
5.9.1.1 | Estradiol (determination of sex hormones) * | Study | 7.80 | 7.83 | 15.63 |
5.9.1.1.2 | Follicle -stimulating hormone (FSH) (determination of sex hormones) FG* | Study | 7.80 | 7.83 | 15.63 |
5.9.1.1.3 | Luteinizing hormone (determination of sex hormones) LH* | Study | 7.80 | 7.83 | 15.63 |
5.9.1.1.4. | Progesterone (determination of sex hormones) | Study | 7.80 | 7.83 | 15.63 |
5.9.1.1.5 | Prolactin (determination of sex hormones) PLN* | Study | 7.80 | 11.65 | 19.45 |
5.9.1.1.6. | Testosterone (determination of sex hormones) TCTN* | Study | 7.80 | 14.26 | 06.22 |
5.9.1.1.7. | Chorionic gonadotropin or its beta-bomb (determination of sex hormones) hCG or B-hCCH* | Study | 7.80 | 9.50 | 17.30 |
5.9.1.1.8. | Tireotropic hormone (TSH) (determination of hormones, thyroid gland) TTG* | Study | 7.80 | 7.44 | 15.24 |
5.9.1.1.9. | Free thyroxine (determination of hormones, thyroid gland) ft4* | Study | 7.80 | 5.32 | 13.12 |
5.9.1.1.10. | Free triiodothyronine (determination of hormones, thyroid gland) FT3* | Study | 7.80 | 6.52 | 14.32 |
5.9.1.1.11. | Prokalcitonin (determination of hormones, other) PCCN | Study | 7.80 | 47.18 | 54.98 |
5.9.1.1.12. | Cortisol (determination of hormones, other) KRL | Study | 7.80 | 21.06 | 28.86 |
5.9.1.1.13. | Anti -TG antibodies to tyroglobulin (determination of hormones, thyroid gland) anti -TG* | Study | 7.80 | 9.88 | 17.68 |
5.9.1.1.14. | DGEA -I4 | Study | 7.80 | 26.00 | 33.80 |
5.9.1.1.15. | 17-ON progesterone | Study | 7.80 | 7.32 | 15.12 |
5.9.1.1.16. | Determination of parathormone | Study | 7.80 | 9.22 | 02/17 |
5.9.1.2.2. | Antibodies antibodies to thyrooperoxidase (determination of hormones, thyroid gland)* | Study | 9.64 | 14.47 | 24.11 |
6. | Studies of hemostasis |
6.6.4. | Determining the content of fibrinogen in plasma on an automatic coagulometer* | Study | 2.57 | 6.87 | 9.44 |
6.31. | Determination of the lupus anticoagulant by the clotting method* | Study | 54.40 | 26.88 | 81.28 |
6.34. | Determination of antitrombin III (AT III) | Study | 31.64 | 26.24 | 57.88 |
6.37. | Determination of protein with an automatic coagulometer | Study | 31.64 | 31.52 | 63.16 |
6.38. | Determination of protein S on an automatic coagulometer | Study | 31.64 | 54.74 | 86.38 |
6.39. | Determination of D-Dimers* | Study | 31.64 | 22.59 | 54.23 |
6.39.1. | Determination of D-Dimers with an express method (immunofluorescent analysis) | Study | 31.64 | 20.26 | 51.90 |
6.40.1. | Determination of activated partial thromboplastin time on an automatic coagulometer (ACTVT)* | Study | 2.58 | 3.72 | 6.30 |
6.40.2. | Determination of prothrombin time (PTV) with thromboplastin calcium mixture with the calculation of many | Study | 2.58 | 12.47 | 15.05 |
6.40.2.1. | Determination of prothrombin time (PTV) with the calculation of many - express tests from capillary blood (finger)* | Study | 2.58 | 8.00 | 10.58 |
6.40.3. | Determination of thrombin time (TV) | Study | 2.58 | 6.16 | 8.74 |
6.40.4 | Determination of anti-ha hemostasis factor | Study | 2.58 | 22.86 | 25.44 |
7. | Immunological studies |
7.2. | Determination of blood groups according to the AVO system in the cross, determination of the Rh factor | Study | 13.92 | 6.87 | 20.79 |
7.4. | Determination of incomplete Rhesus antibodies by conglutination | Study | 44.29 | 1.65 | 45.94 |
7.6. | Direct Cumbsa test | Study | 50.61 | 2.23 | 52.84 |
7.7. | Indirect sample of kumbs | Study | 88.57 | 5.27 | 93.84 |
7.16.2.1. | SRB General (determination of individual blood serum proteins with a turbidimetric method)* | Study | 4.56 | 4.04 | 8.60 |
7.16.2.2. | SRB is ultra -sensitive (determination of individual blood serum proteins with a turbidimetric method) | Study | 4.56 | 2.67 | 7.23 |
7.16.2.3 | Immunoglobulin a* | Study | 4.56 | 5.11 | 9.67 |
7.16.2.4 | Immunoglobulin m* | Study | 4.56 | 5.30 | 9.86 |
7.16.2.5 | Immunoglobulin g* | Study | 4.56 | 5.30 | 9.86 |
7.16.2.6 | Immunoglobulin e* | Study | 4.56 | 13.97 | 18.53 |
7.17.2. | Determining the activity of anti -o - o - streptolizine in blood serum latex test* | Study | 2.99 | 4.47 | 7.46 |
7.19.2.1.1. | Determination of autoantiber towards class M cardiolipin (IGM) by immuno -function analysis, semi -automated calculation | Study | 7.80 | 12.31 | 20.11 |
7.19.2.1.2. | Determination of autoantibodies to class G (IgG) cardiolipin method by immunoformal analysis, semi -automated calculation | Study | 7.80 | 12.31 | 20.11 |
7.19.2.1.3. | Determination of autoantiber to beta 2-glycoprotein class M (IGM) by immuno-function analysis, semi-automated calculation | Study | 7.80 | 12.31 | 20.11 |
7.19.2.1.4. | Determination of autoantiber towards beta2-glycoprotein class G (IgG) by immunofortment analysis, semi-automated calculation | Study | 7.80 | 12.31 | 20.11 |
7.19.2.1.5. | Determination of autoantibodies to nucleosomes by immuno -function analysis, semi -automated calculation* | Study | 7.80 | 12.91 | 20.71 |
7.19.2.1.6. | Determination of autoantel to double-chain DNA (DS-DNA)* | Study | 7.80 | 12.34 | 20.14 |
7.19.2.1.7. | Determination of antinuclear antibodies (ANA)* | Study | 7.80 | 12.34 | 20.14 |
7.19.2.1.8. | Determination of anticytoplasmic antibodies (anca) | Study | 7.80 | 12.34 | 20.14 |
7.19.2.1.9. | Determination of antibodies to cyclical citrulinated peptide (ACCP)* | Study | 7.80 | 14.59 | 22.39 |
7.19.2.1.10 | Determination of autoantibodies to mitochondria (ama) | Study | 7.80 | 12.29 | 09.20 |
7.19.2.1.11 | Determination of autoantibodies to tissue transglutaminase IG A | Study | 7.80 | 11.70 | 19.50 |
7.19.2.1.12 | Determination of autoantiber to tissue transglutaminase IG G | Study | 7.80 | 12.28 | 08.20 |
7.19.2.1.13. | Determination of antibodies to a modified citrulinized viementin (MCV)* | Study | 7.80 | 17.75 | 25.55 |
7.19.2.1.14. | Determination of the rheumatoid factor IG M | Study | 7.80 | 12.28 | 08.20 |
7.19.2.1.15 | Determination of autoantibodies to myeloperoxidase (MRO) | Study | 7.80 | 12.25 | 05.20 |
7.19.2.1.16 | Determination of autoantiber to proteinase-3 (PR-3) | Study | 7.80 | 13.65 | 21.45 |
7.19.2.1.17. | Determination of autoantibodies to the internal factor (KALEA) | Study | 7.80 | 12.97 | 20.77 |
7.19.2.1.18. | Determination of antibodies to gliadin IG A (Anti-Gliadin Iga) | Study | 7.80 | 12.05 | 19.85 |
7.19.2.1.19. | Determination of antibodies to gliadin IG G (Anti-Gliadin IgG) | Study | 7.80 | 12.05 | 19.85 |
7.19.2.1.20. | Determination of antibodies to Saccaharomyces Cerevisiae A (ASCA IG A) | Study | 7.80 | 12.05 | 19.85 |
7.19.2.1.21. | Definition of antibodies to Saccaharomyces Cerevisiae G (ASCA IG G) | Study | 7.80 | 12.05 | 19.85 |
7.19.2.1.22. | Screening of antiphospholipid total antibodies (AT to cardiolipin, beta-2-glycoprotein-1, phosphotydilositol, phosphotididserin) class M Anti-Phospholipid Screen IgM* | Study | 7.80 | 12.05 | 19.85 |
7.19.2.1.23. | Screening of antiphospholipid total antibodies (AT to cardiolipin, beta-2-glycoprotein-1, phosphotydilositol, phosphotididserin) class G Anti-Phospholipid Screen igg* | Study | 7.80 | 12.25 | 05.20 |
7.19.2.1.24. | Determination of antibodies to phosphotylserin class m (AT to phosphotidylserin IG M) | Study | 7.80 | 12.00 | 19.80 |
7.19.2.1.25. | Determination of antibodies to phosphotylserin class G (AT to phosphotidylserin IG G) | Study | 7.80 | 12.00 | 19.80 |
7.19.2.1.26. | Determination of antibodies to Latoferrin (at-K Lacterrin) | Study | 7.80 | 10.07 | 17.87 |
7.19.2.1.27. | Determination of antibodies to a soluble liver antigen (anti-sla) | Study | 7.80 | 15.17 | 22.97 |
7.19.2.1.28. | Determination of antibodies to the microsomes of the liver and kidneys (Anti-LKM-1) | Study | 7.80 | 15.15 | 22.95 |
7.19.2.1.29. | Determination of antibodies to the deaminated peptide of gliadine IG A (anti-dgp ig a) | Study | 7.80 | 12.19 | 19.99 |
7.19.2.1.30. | Determination of antibodies to the deaminated peptide of gliadine Ig G (anti-dgp ig g) | Study | 7.80 | 12.19 | 19.99 |
7.19.2.1.31. | Determination of antibodies to the parietal cells of the stomach IG G (anti-Parietal Cell IgG) | Study | 7.80 | 12.24 | 04.20 |
7.19.2.1.32. | Determination of antibodies to the basal membrane of the Bloons IG G (Anti-GBM IgG) | Study | 7.80 | 13.70 | 21.50 |
7.19.2.1.33. | Determination of antibodies (high-quality) ANA-immunoblotting class 9 parameters | Study | 7.80 | 32.75 | 40.55 |
7.19.2.1.34. | Determination of antibodies (high -quality) -Miosite profile -immunoblotting | Study | 7.80 | 32.75 | 40.55 |
7.19.2.1.35. | Determination of antibodies (high -quality) -anca profile -immunoblotting 3 parameters | Study | 7.80 | 32.75 | 40.55 |
7.19.2.1.36. | Determination of vitamin D2/d3-OH* | Study | 7.80 | 35.66 | 43.46 |
7.19.2.1.37. | Determination of antibodies (high-quality) class ANA-Immunoblotting17 parameters | Study | 7.80 | 45.70 | 53.50 |
7.19.2.1.38. | Insulin definition* | Study | 7.80 | 9.10 | 16.90 |
7.19.2.1.39. | Determination of vitamin in 12* | Study | 7.80 | 15.23 | 23.03 |
7.19.2.1.40. | Determination of pyrilinks-D (bone resorption marker) | Study | 7.80 | 44.18 | 51.98 |
7.19.2.1.41 | Determination of osteocalcine | Study | 7.80 | 19.65 | 27.45 |
7.19.2.1.42 | Determination of the level of folates (vitamin B9, folic acid)* | Study | 7.80 | 20.62 | 28.42 |
7.19.2.1.45 | Determination of ELISA ANTI-SS-A (Reve.) | Study | 7.80 | 19.26 | 27.06 |
7.19.2.1.46 | Determination of ELISA ANTI-SS-B (Reve.) | Study | 7.80 | 19.26 | 27.06 |
7.19.2.1.47 | Determination of ELISA ANTI-SM (Reve.) | Study | 7.80 | 19.26 | 27.06 |
7.19.2.1.48 | Determination of ELISA ANTI-SS-A 52 (Reve.) | Study | 7.80 | 19.26 | 27.06 |
7.19.2.1.49 | Determination of ELISA ANTI-SS-A 60 (Reve.) | Study | 7.80 | 19.26 | 27.06 |
7.19.2.1.50 | Definition of Anti-Rnp/SM ELIS (Reve.) | Study | 7.80 | 19.26 | 27.06 |
7.19.2.1.51 | Determination of ELISA Anti-SCL-70 (Reve.) | Study | 7.80 | 19.26 | 27.06 |
7.19.2.1.52 | Determination of ELISA ANTI-CENTROMERE B (Reve.) | Study | 7.80 | 19.26 | 27.06 |
7.19.2.1.53 | Determination of ELISA ANTI-JO-1 (Reve.) | Study | 7.80 | 19.26 | 27.06 |
7.21.2. | Rheumatoid factor (determination in the blood serum with a latex test)* | Study | 2.99 | 3.22 | 6.21 |
8. | Bacteriological studies |
8.3.1. | Microscopy of stained (according to gram) drugs of native material, sputum, flushing waters of the bronchi, transudates, exudates (studies on aerobic and optional anaerobic microorganisms) | Study | 22.70 | 0.53 | 23.23 |
8.17.9.1.1. | Determination of antigens to Helicobacter pylori in feces (to viral and bacterial antigens method by immunofortment analysis with semi -automated calculations) | Study | 22.15 | 11.66 | 33.81 |
8.17.9.1.2. | Determination of antibodies to Helicobacter pylori in the blood (to viral and bacterial antigens method by immunofortment analysis with semi -automated calculation) | Study | 22.15 | 5.10 | 27.25 |
8.17.9.1.3. | Determination of antibodies (IgG) to the Varicella Zoster virus (to viral and bacterial antigens by immuno -function analysis with semi -automated calculations) | Study | 22.15 | 6.59 | 28.74 |
8.17.9.1.4. | Determination of antibodies (IgM) to toxoplasm* | Study | 22.15 | 7.04 | 29.19 |
8.17.9.1.5. | Determination of antibodies (IgG) to toxoplasm* | Study | 22.15 | 7.80 | 29.95 |
8.17.9.1.6. | Determination of antibodies to cytomegalovirus (IgM CMV)* | Study | 22.15 | 6.35 | 28.50 |
8.17.9.1.7. | Determination of antibodies to cytomegalovirus (IgG CMV)* | Study | 22.15 | 6.26 | 28.41 |
8.17.9.1.8. | Determination of IgG to the early capsid antigen of the Epstein Barra virus (EBV VCA/EA IgG) | Study | 22.15 | 10.05 | 32.20 |
8.17.9.1.9. | Determination of IGM to the capsid antigen of the Epstein Barra virus (EBV VCA IgM) | Study | 22.15 | 10.05 | 32.20 |
8.17.9.1.10. | Determination of IgG to the nuclear antigen of the Epstein Barra virus (EBV Ebna IgG) | Study | 22.15 | 9.40 | 31.55 |
8.17.9.1.11. | Screening test for determining syphilis (RPR-Carbon) | Study | 22.15 | 5.43 | 27.58 |
8.17.9.1.12. | Determination of antibodies (IgG) to the hepatitis C virus (Anti-HCV)* | Study | 22.15 | 13.61 | 35.76 |
8.17.9.1.13. | Determination of high -quality superficial antigen of the hepatitis B (HBS AG Ultra)** | Study | 22.15 | 16.57 | 38.72 |
8.17.9.1.14 | Determination of antibodies (IgM) to rubella (Rubella)* | Study | 22.15 | 6.63 | 28.78 |
8.17.9.1.15 | Determination of antibodies (IG G) to rubella (Rubella)* | Study | 22.15 | 7.03 | 29.18 |
8.17.9.1.16 | Determination of antibodies (IGM) to the herpes simplex virus type 1/2* | Study | 22.15 | 17.25 | 39.40 |
8.17.9.1.17 | Determination of antibodies (IgG) to the herpes simplex virus type 1/2* | Study | 22.15 | 13.84 | 35.99 |
8.17.9.1.18. | Determination of IGG Avity to cytomegalovirus | Study | 22.15 | 26.66 | 48.81 |
8.17.9.1.19 | Determination of IGG Avil to toxoplasm* | Study | 22.15 | 18.78 | 40.93 |
8.17.9.1.20 | Determination of antibodies (IG G) to AT to Chlamydia pneumoniae in serum | Study | 22.15 | 05/17 | 39.20 |
8.17.9.1.21 | Determination of antibodies (Ig a) to Mycoplasma | Study | 22.15 | 14.30 | 36.45 |
8.17.9.1.22 | Determination of antibodies (IG M with absorption) to AT to Mycoplasma Pneumoniae in serum | Study | 22.15 | 17.18 | 39.33 |
8.17.9.1.23 | Determination of antibodies (IG G) to Mycoplasma pneumoniae in serum | Study | 22.15 | 14.30 | 36.45 |
8.17.9.1.24 | Determination of antibodies (IG A) to at AT to Chlamydia pneumoniae in serum | Study | 22.15 | 19.40 | 41.55 |
8.17.9.1.25 | Determination of antibodies (IG m with absorption) to AT to Chlamydia pneumoniae in serum | Study | 22.15 | 20.75 | 42.90 |
8.17.9.1.26 | Determination of antibodies (m, g) to Sars-Cov-2 in the blood | Study | 22.15 | 11.72 | 33.87 |
8.17.9.1.27 | Determination of Interlikin L-6 | Study | 22.15 | 27.06 | 49.21 |
8.17.9.4.1. | Determination of immunoglobulins (antibodies) of one class to chlamydia Trachomatis (IG G) with manual calculation of the positiveness coefficient and antibodies titer* | Study | 23.43 | 15.98 | 39.41 |
8.17.9.4.2. | Determination of immunoglobulins (antibodies) of one class to chlamydia Trochomatis (IG A) with manual calculation of the positiveness coefficient and antibodies titer* | Study | 23.43 | 15.92 | 39.35 |
8.17.9.4.3. | Determination of immunoglobulins (antibodies) of one class to chlamydia Trochomatis-IGM (with the absorbent of the Russian Federation)* | procedure | 23.43 | 19.36 | 42.79 |
9. | Genetic studies |
9.7. | Looping tests with glucose (glucosotolerant test-GGT 2 multiple) | Study | 4.47 | 1.64 | 6.11 |